193 related articles for article (PubMed ID: 22507985)
21. Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge.
Koya V; Moayeri M; Leppla SH; Daniell H
Infect Immun; 2005 Dec; 73(12):8266-74. PubMed ID: 16299323
[TBL] [Abstract][Full Text] [Related]
22. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen.
Gu ML; Leppla SH; Klinman DM
Vaccine; 1999 Jan; 17(4):340-4. PubMed ID: 9987172
[TBL] [Abstract][Full Text] [Related]
23. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice.
Welkos SL; Friedlander AM
Microb Pathog; 1988 Aug; 5(2):127-39. PubMed ID: 3148815
[TBL] [Abstract][Full Text] [Related]
24. Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4.
McConnell MJ; Hanna PC; Imperiale MJ
Infect Immun; 2006 Feb; 74(2):1009-15. PubMed ID: 16428747
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults.
Brown BK; Cox J; Gillis A; VanCott TC; Marovich M; Milazzo M; Antonille TS; Wieczorek L; McKee KT; Metcalfe K; Mallory RM; Birx D; Polonis VR; Robb ML
PLoS One; 2010 Nov; 5(11):e13849. PubMed ID: 21079762
[TBL] [Abstract][Full Text] [Related]
26. Bacillus anthracis protective antigen, expressed in Salmonella typhimurium SL 3261, affords protection against anthrax spore challenge.
Coulson NM; Fulop M; Titball RW
Vaccine; 1994 Nov; 12(15):1395-401. PubMed ID: 7887017
[TBL] [Abstract][Full Text] [Related]
27. [Molecular mechanisms underlying bacillus anthracis infection at early stages and search for novel vaccines].
Stepanov AV; Marinin LI; Staritsyn NA; Noskov AN; Borovkova LV; Kravchenko TB
Vestn Ross Akad Med Nauk; 1997; (6):16-20. PubMed ID: 9289272
[TBL] [Abstract][Full Text] [Related]
28. Anthrax toxin: a tripartite lethal combination.
Ascenzi P; Visca P; Ippolito G; Spallarossa A; Bolognesi M; Montecucco C
FEBS Lett; 2002 Nov; 531(3):384-8. PubMed ID: 12435580
[TBL] [Abstract][Full Text] [Related]
29. Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax.
Cohen S; Mendelson I; Altboum Z; Kobiler D; Elhanany E; Bino T; Leitner M; Inbar I; Rosenberg H; Gozes Y; Barak R; Fisher M; Kronman C; Velan B; Shafferman A
Infect Immun; 2000 Aug; 68(8):4549-58. PubMed ID: 10899854
[TBL] [Abstract][Full Text] [Related]
30. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs.
Little SF; Ivins BE; Fellows PF; Friedlander AM
Infect Immun; 1997 Dec; 65(12):5171-5. PubMed ID: 9393812
[TBL] [Abstract][Full Text] [Related]
31. Immunization studies with attenuated strains of Bacillus anthracis.
Ivins BE; Ezzell JW; Jemski J; Hedlund KW; Ristroph JD; Leppla SH
Infect Immun; 1986 May; 52(2):454-8. PubMed ID: 3084383
[TBL] [Abstract][Full Text] [Related]
32. Additional conjugation methods and immunogenicity of Bacillus anthracis poly-gamma-D-glutamic acid-protein conjugates.
Kubler-Kielb J; Liu TY; Mocca C; Majadly F; Robbins JB; Schneerson R
Infect Immun; 2006 Aug; 74(8):4744-9. PubMed ID: 16861662
[TBL] [Abstract][Full Text] [Related]
33. [The effect of the protective antigen of Bacillus anthracis on the formation of immunity under the action of live anthrax vaccines].
Abalakin VA; Buravtseva NP; Cherkasskiĭ BL
Zh Mikrobiol Epidemiol Immunobiol; 1990 May; (5):72-5. PubMed ID: 2117320
[TBL] [Abstract][Full Text] [Related]
34. Passive transfer of protection against Bacillus anthracis infection in a murine model.
Beedham RJ; Turnbull PC; Williamson ED
Vaccine; 2001 Aug; 19(31):4409-16. PubMed ID: 11483266
[TBL] [Abstract][Full Text] [Related]
35. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig.
Little SF; Knudson GB
Infect Immun; 1986 May; 52(2):509-12. PubMed ID: 3084385
[TBL] [Abstract][Full Text] [Related]
36. A heat-inducible Bacillus subtilis bacteriophage phi 105 expression system for the production of the protective antigen of Bacillus anthracis.
Baillie LW; Moore P; McBride BW
FEMS Microbiol Lett; 1998 Jun; 163(1):43-7. PubMed ID: 9631544
[TBL] [Abstract][Full Text] [Related]
37. Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals.
Iacono-Connors LC; Welkos SL; Ivins BE; Dalrymple JM
Infect Immun; 1991 Jun; 59(6):1961-5. PubMed ID: 1903769
[TBL] [Abstract][Full Text] [Related]
38. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants.
Ivins BE; Welkos SL; Little SF; Crumrine MH; Nelson GO
Infect Immun; 1992 Feb; 60(2):662-8. PubMed ID: 1730501
[TBL] [Abstract][Full Text] [Related]
39. Protective antigen-mediated antibody response against a heterologous protein produced in vivo by Bacillus anthracis.
Brossier F; Weber-Levy M; Mock M; Sirard JC
Infect Immun; 2000 Oct; 68(10):5731-4. PubMed ID: 10992478
[TBL] [Abstract][Full Text] [Related]
40. Use of a promoter trap system in Bacillus anthracis and Bacillus subtilis for the development of recombinant protective antigen-based vaccines.
Gat O; Inbar I; Aloni-Grinstein R; Zahavy E; Kronman C; Mendelson I; Cohen S; Velan B; Shafferman A
Infect Immun; 2003 Feb; 71(2):801-13. PubMed ID: 12540560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
